Form 4: Agios Pharmaceuticals Director Executes Options and Sells Shares Under Pre-Arranged 10b5-1 Plan

Agios Pharmaceuticals Director David Scadden exercised stock options and simultaneously sold an equal number of common shares on July 10, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Scadden, a Director of Agios Pharmaceuticals, Inc. (AGIO), engaged in transactions on July 10, 2025.
• Scadden exercised stock options to acquire 1,400 shares of common stock at an exercise price of $18.09 per share.
• Concurrently, Scadden sold 1,400 shares of common stock at a price of $40 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Scadden's direct beneficial ownership of common stock decreased from 19,003 to 17,603 shares.
• His beneficial ownership of stock options decreased from an implied 29,107 to 27,707 after the exercise of 1,400 options.

Sentiment

Score: 6

Explanation: The transaction is neutral to slightly positive. While it's an insider sale, it's under a 10b5-1 plan, which mitigates negative perception. The significant profit from option exercise and sale is a positive for the insider, but the reduction in direct ownership is a slight negative from a market perspective.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned activity and reducing concerns about opportunistic insider trading.
• The sale price of $40 per share is significantly higher than the exercise price of $18.09, indicating a profitable transaction for the insider.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale by a director reduces insider ownership, which could be viewed neutrally or slightly negatively, though the 10b5-1 plan mitigates concerns. The transaction itself does not directly impact other stakeholders like employees, customers, suppliers, or creditors.

Key Dates

Recommendation

Keywords

Agios Pharmaceuticals, AGIO, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Director, Share Sale, Equity Transaction